ABLi reports biomarker findings from risvodetinib study for Parkinson’s

Data ReadoutrisvodetinibNeutral

AI Analysis

Summary

ABLi Therapeutics completed a biomarker analysis from its Phase II 201 trial of risvodetinib for Parkinson's disease. No specific efficacy or safety outcomes were disclosed in this announcement.

Clinical Trial Data

Phase

Phase 2

Outcome Details

Biomarker analysis completed from Phase II 201 Trial

Importance:4/10

Sentiment:

0.00

Parkinson's diseasebiomarker analysisPhase 2risvodetinib

Related Companies

$TRAX $ARNA

Read the original article

Published by Clinical Trials Arena on August 5, 2026 9:32 AM

Read Original